Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
SGRY · against 588 other Healthcare companies listed in US-listed
Ranked #153 of 589 · scores higher than 73% of peers
Bars: peers in each 10-point band of the valuation score57 peers with a valuation score of 50–59, including SGRY · Click a bar to see the companies
A mix: stronger free cash flow yield and EBITDA yield, but weaker earnings yield than most Healthcare peers.
| Metric | SGRY | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 577 reported | -3.0% | -4.3% | 53% | 30% | |
| EBITDA yieldHigher is better · 578 reported | 7.5% | -0.8% | 80% | 50% | |
| Free cash flow yieldHigher is better · 553 reported | 6.2% | -2.3% | 87% | 20% | |
| Book yieldHigher is better · 587 reported | 55.7% | 25.9% | 78% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 256M USD | 98 | 80 | |
| 2 | 595M USD | 96 | 97 | |
| 2 | 433M USD | 96 | 81 | |
| 2 | 289M USD | 96 | 57 | |
| 2 | 810M USD | 96 | 69 | |
| 144 | 8.4B USD | 57 | 67 | |
| 151 | 3.0B USD | 56 | 35 | |
| 151 | 356M USD | 56 | 35 | |
| 153 | 1.6B USD | 55 | 51 | |
| 153 | 3.0B USD | 55 | 39 | |
| 153 | 48.9B USD | 55 | 54 | |
| 153 | 9.3B USD | 55 | 64 | |
| 153 | 134.5B USD | 55 | 70 | |
| 158 | 406M USD | 54 | 59 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score